Workflow
Oppenheimer(OPY)
icon
Search documents
Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
GlobeNewswire News Room· 2025-02-04 13:00
Company Overview - Avalo Therapeutics, Inc. is a clinical stage biotechnology company focused on the treatment of immune dysregulation [3] - The company's lead asset is AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases [3] - Avalo has two additional drug candidates: quisovalimab (anti-LIGHT monoclonal antibody) and AVTX-008 (BTLA agonist fusion protein) [3] Product Details - AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity [4] - IL-1β is a central driver in the inflammatory process and is implicated in many autoimmune and inflammatory diseases [4] - Evidence suggests that inhibition of IL-1β could be effective in treating hidradenitis suppurativa and various inflammatory diseases in dermatology, gastroenterology, and rheumatology [4] Upcoming Events - Garry A. Neil, M.D., CEO and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 10:00 a.m. ET [1] - A live webcast and replay of the presentation will be available on the Avalo Therapeutics website for at least 30 days [2]
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Prnewswire· 2025-02-04 13:00
Group 1 - Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing innovative medicines targeting microRNAs [3] - The management team will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11th at 2:40 p.m. ET [1] - The live event and replay will be available on the company's investor relations website for 90 days following the presentation [2] Group 2 - Regulus has developed a pipeline supported by a strong intellectual property estate in the microRNA field [3] - The company is headquartered in San Diego, CA [3]
Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
GlobeNewswire News Room· 2025-02-04 12:30
Company Overview - Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [3] - The company utilizes its TMAb™ platform to create conditionally active therapeutics that target the tumor microenvironment [3] Product Development - Sensei's lead product candidate is solnerstotug, an antibody designed to block the VISTA checkpoint selectively in the low pH tumor microenvironment [3] - The mechanism of solnerstotug involves disabling immunosuppressive signals to activate T cells against tumors [3] Upcoming Events - John Celebi, President and CEO of Sensei, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 10:40 a.m. ET [1] - A webcast of the presentation will be available on the company's website, with a replay accessible for approximately 90 days [2]
I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
GlobeNewswire News Room· 2025-02-04 12:30
Core Points - I-Mab, a U.S.-based global biotech company, focuses on developing precision immuno-oncology agents for cancer treatment [2] - The management team of I-Mab will participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11-12, 2025 [1] - The conference will include a company presentation and one-on-one meetings, with I-Mab's presentation scheduled for February 11, 2025, from 4:00 to 4:30 PM ET [1] Company Overview - I-Mab is headquartered in Rockville, Maryland, and has operations in Short Hills, New Jersey [2] - The company specializes in precision immuno-oncology, targeting cancer treatment [2] Contact Information - Investor and media inquiries can be directed to PJ Kelleher at LifeSci Advisors [3] - Contact details include a phone number and email for investor relations [3]
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Newsfile· 2025-02-04 12:27
Core Viewpoint - Cardiol Therapeutics Inc. is set to present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, focusing on its clinical-stage anti-inflammatory and anti-fibrotic therapies for heart disease [1]. Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company specializing in the research and development of therapies targeting inflammation and fibrosis in heart disease [3]. - The company's lead drug candidate, CardiolRx™ (cannabidiol) oral solution, is in clinical development and aims to inhibit the inflammasome pathway, which is crucial in the progression of inflammation and fibrosis related to heart conditions [3]. Clinical Development - Cardiol has received Investigational New Drug Application authorization from the US FDA to conduct clinical studies for CardiolRx™ in recurrent pericarditis and acute myocarditis [4]. - The MAVERIC Program addresses recurrent pericarditis, which can lead to severe symptoms and reduced quality of life, and includes a completed Phase II study and an ongoing Phase III trial [4]. - The ongoing ARCHER trial is a Phase II study focusing on acute myocarditis, a significant cause of heart failure and sudden cardiac death in young adults [4]. Additional Developments - Cardiol is also developing CRD-38, a novel subcutaneous formulation intended for heart failure treatment, which is a leading cause of death and hospitalization, with healthcare costs in the US exceeding $30 billion annually [5].
Oppenheimer(OPY) - 2024 Q4 - Annual Results
2025-01-31 13:39
Exhibit 99.1 Oppenheimer Holdings Inc. Reports Fourth Quarter and Full Year 2024 Earnings New York, January 31, 2025 – Oppenheimer Holdings Inc. (NYSE: OPY) (the "Company" or "Firm") today reported net income of $10.7 million or $1.04 basic earnings per share for the fourth quarter of 2024 compared with net income of $11.1 million or $1.07 basic earnings per share for the fourth quarter of 2023. Fourth quarter and full year 2024 results were significantly impacted by higher pre-tax compensation expenses for ...
Oppenheimer Holdings Inc. Reports Fourth Quarter and Full Year 2024 Earnings
Prnewswire· 2025-01-31 13:00
NEW YORK, Jan. 31, 2025 /PRNewswire/ - Oppenheimer Holdings Inc. (NYSE: OPY) (the "Company" or "Firm") today reported net income of $10.7 million or $1.04 basic earnings per share for the fourth quarter of 2024 compared with net income of $11.1 million or $1.07 basic earnings per share for the fourth quarter of 2023. Fourth quarter and full year 2024 results were significantly impacted by higher pre-tax compensation expenses for liability-based awards totaling $20.5 million and $32.6 million, respectively, ...
NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Newsfile· 2025-01-29 22:00
NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceJanuary 29, 2025 5:00 PM EST | Source: NervGen Pharma Corp.Vancouver, Canada--(Newsfile Corp. - January 29, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences C ...
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Prnewswire· 2025-01-29 21:14
PLYMOUTH MEETING, Pa., Jan. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that Dr. Jacqueline Shea, INOVIO's President and CEO, and Dr. Michael Sumner, Chief Medical Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.Oppenheimer 35th Annual Healthcare Life Sciences Conference  ...
XTI Aerospace Adds David Oppenheimer to its Corporate Advisory Board
Prnewswire· 2025-01-14 14:00
ENGLEWOOD, Colo., Jan. 14, 2025 /PRNewswire/ -- XTI Aerospace, Inc. (Nasdaq: XTIA) ("XTI Aerospace" or the "Company"), a pioneer in VTOL and Powered-Lift aircraft solutions, today announced that David Oppenheimer has joined the XTI Corporate Advisory Board.Mr. Oppenheimer is a seasoned professional with over 40 years of experience in advancing emerging technologies and national policy. He has led global research teams focused on advanced analog computing based on neural networking theories and optical displ ...